BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM Galectin-3 Test

BG Medicine Announces Obtaining CE Mark and Launching of Automated BGM
Galectin-3 Test

First Automated Test Launches in Europe and Territories Recognizing the CE

WALTHAM, Mass., Jan. 2, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.
(Nasdaq:BGMD), a company focused on the development and commercialization of
novel cardiovascular diagnostics, announced today that the first automated
version of the BGM Galectin-3^® blood test has obtained a CE Mark, an
important step in the company's commercial strategy. 

The BGM Galectin-3 test will be distributed through bioMérieux's VIDAS^®
immunoassay platform which includes about 27,000 installed instruments
worldwide. bioMérieux is one of four diagnostic instrument manufacturers
partnering with BG Medicine to commercialize automated versions of the BGM
Galectin-3 test, and the first to obtain a CE Mark. bioMérieux is preparing a
phased launch of the test in Europe and in certain other territories that
recognize the CE Mark.

"The BGM Galectin-3 test has the potential to play a major role in improving
the management of heart failure," said Eric Bouvier, President and Chief
Executive Officer of BG Medicine."The launch of the first automated version
of our test is a watershed and exciting moment for our company. Through its
broad CE-marked installed base, bioMérieux is in a position to drive the
adoption of the test in Europe. Offering an automated version of the
galectin-3 assay is critical for us to obtain broad-based and rapid global
adoption. Partnering with bioMérieux, as well as Abbott, Alere and Siemens
provides BG Medicine tremendous international coverage to drive commercial
adoption over the next several years."

The CE Mark for bioMérieux's automated version of the BGM Galectin-3 test is
the latest in a series of steps designed to further BG Medicine's
three-pillared business model for the test, which is focused on rapid
commercial adoption driven by sales through automated partners, specialized
labs and the targeting of US hospitals with high readmissions rates.Recent
developments in this commercial strategy have included:

  oThe launch of a major campaign to grow BGM Galectin-3 test sales in
    hospital settings. BG Medicine launched a new campaign in November 2012
    focused on the urgent need to reduce rates of unplanned hospital
    readmissions. The Centers for Medicare & Medicaid Services (CMS)
    guidelines that went into effect on October 1, 2012 will result in new
    financial penalties expected to reach an aggregate of nearly $300 million
    in 2013 and nearly $1 billion by 2015, if improvements are not made.
    Because heart failure patients with elevated levels of galectin-3 are
    two-to-three times more likely than other heart failure patients to be
    readmitted to the hospital within 30 days of discharge, the company
    believes that identifying and risk-stratifying these high-risk patients
    through galectin-3 testing is a potentially valuable and cost-effective
    tool in a hospital's strategy to reduce unplanned 30-day readmissions. The
    company expects this initiative will accelerate the sales ramp-up and the
    widespread adoption of galectin-3 testing.
  oThe conversion of a medical liaison organization to a US-based sales
    organization. BG Medicine is transforming its current field force from an
    awareness- and education-focused organization into one with a sales
    mission and growth strategy. The field force will focus initially on
    promoting galectin-3 testing at a core set of hospitals with
    higher-than-average readmission rates, which are at risk of incurring
    significant financial penalties due to new rules affecting readmissions
    set by CMS.
  oThe opening of a CLIA (Clinical Laboratory Improvement Amendments)
    certified clinical laboratory. BG Medicine expects to open the BG Medicine
    CLIA laboratory in the first half of 2013 in order to make galectin-3
    testing available to more hospitals and other health care providers. The
    company expects this CLIA lab will further strengthen the company's own
    infrastructure to support sales made directly by BG Medicine.

"2013 is poised to be a year of great progress in our commercial strategy for
the manual and automated versions of the BGM Galectin-3 test and we are
pleased to begin the year with this important development in the execution of
this strategy," continued Mr. Bouvier.

About Galectin-3 and Heart Failure

Galectin-3 is a unique carbohydrate-binding lectin, or protein, that binds to
carbohydrates called beta-galactosides.Galectin-3 has been implicated in a
variety of biological processes important in the development and progression
of heart failure, and is believed to be a primary mediator of progressive
cardiac fibrosis (abnormal thickening and stiffening of the heart muscle) and
adverse remodeling (changes in the structure of the heart). Higher levels of
galectin-3 are associated with a more aggressive form of heart failure and 30%
or more of mild to moderate heart failure patients will have elevated levels
of galectin-3. Heart failure affects an estimated 5.8 million Americans, with
approximately 670,000 new cases occurring each year.The direct and indirect
cost of heart failure in the United States for 2010 is estimated to be $39.2

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD) is a diagnostics company focused on the
development and commercialization of novel cardiovascular tests to address
significant unmet medical needs, improve patient outcomes and reduce
healthcare costs. The Company has two products: the BGM Galectin-3^® test for
use in patients with chronic heart failureis available in the United States
and Europe;and theCardioSCORE™test for the risk prediction of major
cardiovascular events will be launched in Europe in the first half of
2013.For additional information about BG Medicine, heart failure and
galectin-3 testing, please visit and

The BG Medicine Inc. logo is available at

Forward-Looking Statements

Certain statements made in this news release contain forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities and Exchange Act of 1934, as
amended, that are intended to be covered by the "safe harbor" created by those
sections. Forward-looking statements, which are based on certain assumptions
and describe our future plans, strategies and expectations, can generally be
identified by the use of forward-looking terms such as "believe," "expect,"
"may," "will," "should," "could," "seek," "intend," "plan," "estimate,"
"anticipate" or other comparable terms. Forward-looking statements in this
news release address our beliefs that bioMérieux, as our first partner to
launch an automated version of our galectin-3 test, is in a position to drive
the adoption of galectin-3 testing in Europe; our belief that identifying and
risk-stratifying high-risk patients through galectin-3 testing is a
potentially valuable and cost-effective tool in a hospital's strategy to
reduce unplanned 30-day readmissions; our expectations that our hospital
readmissions initiative will accelerate the sales ramp-up and adoption of
galectin-3 testing; our expectation that we will open our own CLIA lab in the
first half of 2013; and our expectations that having our own CLIA lab will
further strengthen our ability to strengthen sales of our diagnostic
tests.Forward-looking statements are based on management's current
expectations and involve inherent risks and uncertainties which could cause
actual results to differ materially from those in the forward-looking
statements, as a result of various factors including those risks and
uncertainties described in the Risk Factors and in Management's Discussion and
Analysis of Financial Condition and Results of Operations sections of our
recent filings with the Securities and Exchange Commission, including our most
recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge
you to consider those risks and uncertainties in evaluating our
forward-looking statements. We caution readers not to place undue reliance
upon any such forward-looking statements, which speak only as of the date
made. Except as otherwise required by the federal securities laws, we disclaim
any obligation or undertaking to publicly release any updates or revisions to
any forward-looking statement contained herein (or elsewhere) to reflect any
change in our expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.

CONTACT: Chuck Abdalian
         EVP & Chief Financial Officer
         (781) 434-0210

BG Medicine Inc. logo
Press spacebar to pause and continue. Press esc to stop.